TaiMed Biologics Asset Resilience Ratio
TaiMed Biologics asset resilience ratio. TaiMed Biologics (4147) has an Asset Resilience Ratio of 13.57% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 4147 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of TaiMed Biologics (2013–2025)
Asset resilience ratio of TaiMed Biologics from 2013 to 2025. This chart shows how TaiMed Biologics's Asset Resilience Ratio has changed over time. Read total liabilities of TaiMed Biologics for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down TaiMed Biologics's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see TaiMed Biologics (4147) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$610.75 Million | 13.57% |
| Total Liquid Assets | NT$610.75 Million | 13.57% |
Asset Resilience Insights
- Moderate Liquidity: TaiMed Biologics has 13.57% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
TaiMed Biologics Industry Peers by Asset Resilience Ratio
Compare TaiMed Biologics's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
TaiMed Biologics Asset Resilience Ratio by Year (2013–2025)
TaiMed Biologics asset resilience ratio by year from 2013 to 2025. The table below shows the annual Asset Resilience Ratio data for TaiMed Biologics.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 18.13% | NT$872.35 Million ≈ $27.48 Million |
NT$4.81 Billion ≈ $151.56 Million |
-3.36pp |
| 2024-12-31 | 21.50% | NT$1.07 Billion ≈ $33.86 Million |
NT$5.00 Billion ≈ $157.50 Million |
+11.27pp |
| 2023-12-31 | 10.22% | NT$398.13 Million ≈ $12.54 Million |
NT$3.89 Billion ≈ $122.68 Million |
+1.17pp |
| 2022-12-31 | 9.05% | NT$371.29 Million ≈ $11.70 Million |
NT$4.10 Billion ≈ $129.21 Million |
+0.18pp |
| 2021-12-31 | 8.88% | NT$409.27 Million ≈ $12.89 Million |
NT$4.61 Billion ≈ $145.26 Million |
-3.28pp |
| 2020-12-31 | 12.15% | NT$631.57 Million ≈ $19.90 Million |
NT$5.20 Billion ≈ $163.71 Million |
-7.33pp |
| 2019-12-31 | 19.48% | NT$921.55 Million ≈ $29.03 Million |
NT$4.73 Billion ≈ $149.04 Million |
-10.28pp |
| 2018-12-31 | 29.76% | NT$1.43 Billion ≈ $44.92 Million |
NT$4.79 Billion ≈ $150.94 Million |
-13.20pp |
| 2017-12-31 | 42.97% | NT$1.93 Billion ≈ $60.95 Million |
NT$4.50 Billion ≈ $141.87 Million |
-7.68pp |
| 2016-12-31 | 50.65% | NT$2.43 Billion ≈ $76.62 Million |
NT$4.80 Billion ≈ $151.28 Million |
-3.59pp |
| 2015-12-31 | 54.24% | NT$2.67 Billion ≈ $84.19 Million |
NT$4.93 Billion ≈ $155.21 Million |
-5.04pp |
| 2014-12-31 | 59.28% | NT$1.11 Billion ≈ $35.13 Million |
NT$1.88 Billion ≈ $59.25 Million |
+20.21pp |
| 2013-12-31 | 39.07% | NT$279.25 Million ≈ $8.80 Million |
NT$714.72 Million ≈ $22.52 Million |
-- |
About TaiMed Biologics
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinica… Read more